Kyoko Kato1, Yukiya Narita2, Seiichiro Mitani1,3, Kazunori Honda1, Toshiki Masuishi1, Hiroya Taniguchi1,4, Shigenori Kadowaki1, Takashi Ura1,5, Masashi Ando1, Masahiro Tajika6, Kei Muro1. 1. Department of Clinical Oncology, Aichi Cancer Centre Hospital, Aichi, Japan. 2. Department of Clinical Oncology, Aichi Cancer Centre Hospital, Aichi, Japan yukiya.narita@aichi-cc.jp. 3. Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan. 4. Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Centre Hospital East, Chiba, Japan. 5. Department of Clinical Oncology, National Hospital Organisation Kyoto Medical Centre, Kyoto, Japan. 6. Department of Endoscopy, Aichi Cancer Centre Hospital, Aichi, Japan.
Abstract
BACKGROUND/AIM: The efficacy of treatment using the anti-programmed cell death-1 (anti-PD-1) antibody for metastatic gastric cancer (mGC) has been established previously. Exploratory analyses in various types of tumours suggest that prior exposure to immune checkpoint inhibitors can enhance the efficacy of subsequent cytotoxic chemotherapy (CTx). Our aim is to evaluate the efficacy and safety of CTx for mGC after progression on anti-PD-(ligand) 1 [anti-PD-(L)1] antibody. PATIENTS AND METHODS: We retrospectively evaluated patients with mGC who underwent CTx. The patients received CTx after progression on anti-PD-(L)1 antibody (cohort A) or as a third-line treatment without prior exposure to anti-PD-(L)1 antibody (cohort B). We evaluated: i) clinical characteristics, ii) efficacies, iii) prognoses, and iv) adverse events (AEs). RESULTS: In cohorts A and B, 16 and 68 patients fulfilled the criteria, respectively. In the univariate analysis, the overall response rate was significantly higher in cohort A compared to cohort B (31% vs. 10%, respectively; Odds Ratio:3.96, 95% Confidence Interval:1.06-14.8, p=0.040). The multivariate analysis showed a similar trend. Immune-related AEs did not worsen and were manageable, while new immune-related AEs were not observed. CONCLUSION: CTx after progression on anti-PD-(L)1 antibody demonstrated a favourable efficacy in intensively treated patients with mGC. Copyright
BACKGROUND/AIM: The efficacy of treatment using the anti-programmed cell death-1 (anti-PD-1) antibody for metastatic gastric cancer (mGC) has been established previously. Exploratory analyses in various types of tumours suggest that prior exposure to immune checkpoint inhibitors can enhance the efficacy of subsequent cytotoxic chemotherapy (CTx). Our aim is to evaluate the efficacy and safety of CTx for mGC after progression on anti-PD-(ligand) 1 [anti-PD-(L)1] antibody. PATIENTS AND METHODS: We retrospectively evaluated patients with mGC who underwent CTx. The patients received CTx after progression on anti-PD-(L)1 antibody (cohort A) or as a third-line treatment without prior exposure to anti-PD-(L)1 antibody (cohort B). We evaluated: i) clinical characteristics, ii) efficacies, iii) prognoses, and iv) adverse events (AEs). RESULTS: In cohorts A and B, 16 and 68 patients fulfilled the criteria, respectively. In the univariate analysis, the overall response rate was significantly higher in cohort A compared to cohort B (31% vs. 10%, respectively; Odds Ratio:3.96, 95% Confidence Interval:1.06-14.8, p=0.040). The multivariate analysis showed a similar trend. Immune-related AEs did not worsen and were manageable, while new immune-related AEs were not observed. CONCLUSION: CTx after progression on anti-PD-(L)1 antibody demonstrated a favourable efficacy in intensively treated patients with mGC. Copyright
Authors: Archana Thakur; Johnson Ung; Elyse N Tomaszewski; Amy Schienschang; Timothy M LaBrie; Dana L Schalk; Lawrence G Lum Journal: Oncoimmunology Date: 2021-06-01 Impact factor: 8.110